Strategic Fund Shifts
Patton Fund Management Expands Industrials and Logistics Holdings, Trims Biopharma in Q1 Repositioning
Key Points
Patton's Cummins stake underscores the stock's high level of institutional ownership, with hedge funds and other institutional investors owning 83.46% of Cummins' stock.
Goldman Sachs Group Inc. boosted its CHRW stake by 24,788 shares in the first quarter, bringing its total to 804,215 shares valued at about $82.35 million.
Jefferies Financial Group began coverage on Gilead Sciences in a research note, adding a new analytical view on the biopharmaceutical name amid broader fund activity.
Patton's Vanguard Real Estate ETF (VNQ) stake rose to 68,856 shares (up 24.7%), worth about $6.108 million, making VNQ roughly 1% of the portfolio and Patton's 12th-largest position.
Patton expanded its Huntington Ingalls Industries (HII) position to 10,606 shares after purchasing 9,888 more, with the stake valued at about $4.029 million and ranking as Patton's 27th-biggest holding.
Patton Fund Management Inc. made sweeping moves in Q1 2026, dramatically increasing stakes in industrial and logistics stocks while cutting its position in a major biopharma name. The Dallas-based hedge fund boosted its C.H. Robinson Worldwide ($CHRW) stake by 1,716.0% and its Cummins ($CMI) position by 1,505.8%, according to Watchlist News, signaling a sharp rotation toward hard-asset and infrastructure-linked equities.
The fund's total 13F portfolio stood at roughly $588.7 million as of March 31, 2026, per WhaleWisdom. Its top 10 holdings make up 33.72% of the portfolio. The moves reflect a clear "risk-on" bet on industrials and logistics — and a pullback from biopharmaceuticals.
Cummins and C.H. Robinson Get Massive New Bets
Patton added 6,793 shares of Cummins in Q1, bringing its total to 7,242 shares, according to Watchlist News. The position is now Patton's 28th-largest holding, worth roughly $2.1 million. Cummins is heavily owned by institutions — hedge funds and institutional investors control 83.46% of its stock, per MarketBeat.
The C.H. Robinson position grew even more dramatically. Patton added 24,110 shares, reaching 25,515 total. That stake is worth about $4.8 million and makes up roughly 0.7% of the portfolio. C.H. Robinson's share price hit $191.13 on June 11, 2026 — a 101.19% jump from the prior year — validating the aggressive accumulation, according to Fintel.
Patton Trims Gilead Even as Analysts Stay Bullish
Patton sold 38,011 shares of Gilead Sciences ($GILD) during Q1, cutting its position by 63.8%. It ended the quarter with 21,594 shares worth about $3.01 million. The move looks like tactical profit-taking. Twenty-five research analysts still hold a "Buy" rating on Gilead, according to MarketBeat.
Jefferies Financial Group initiated coverage on Gilead in March with a "Buy" rating and a $180 price target, citing a strong HIV franchise and "no major near-term intellectual property cliffs," per Investing.com. Then in June, the European Commission approved Gilead's cancer drug Trodelvy as a first-line treatment for metastatic triple-negative breast cancer — a major pipeline win that came after Patton had already sold.
Defense and Real Estate Round Out the Repositioning
Patton added 9,888 shares of Huntington Ingalls Industries ($HII), a 1,377.2% increase, bringing its total to 10,606 shares. The stake is worth about $4.03 million and ranks as the fund's 27th-biggest holding. HII posted 13.4% revenue growth, but Wall Street holds a cautious consensus "Hold" rating on the stock, per MarketBeat.
Patton also raised its Vanguard Real Estate ETF ($VNQ) stake by 24.7%, reaching 68,856 shares worth about $6.11 million. VNQ is now the fund's 12th-largest position at roughly 1% of the portfolio. The move into a rate-sensitive asset like VNQ suggests the fund may be positioning for a Federal Reserve policy shift later in 2026.
Goldman Sachs Also Builds Its CHRW Stake in Q1
Patton was not the only big player adding to C.H. Robinson. Goldman Sachs boosted its CHRW stake by 24,788 shares in Q1, bringing its total to 804,215 shares valued at about $82.35 million, per MarketBeat. The parallel moves by two large institutions suggest growing conviction in logistics as supply chains stabilize at higher price points.
Goldman CEO David Solomon struck a confident tone in late June, saying the firm's CCAR results reflect "the continued strength of our earnings and capital position... and our confidence in our ability to support clients and deliver sustainable returns." The broader institutional push into industrials and logistics points to a shared view: manufacturing and transport demand is not cooling anytime soon.
Sentiment
Mostly PositivePublishers
12
Articles
13
Reach
25
